Clinicopathological Outlines of Post-COVID-19 Pulmonary Fibrosis Compared with Idiopathic Pulmonary Fibrosis.
Roxana-Elena CîrjaliuMariana DeacuIoana GherghișanAngela Ștefania MarghescuManuela EnciuGabriela Isabela BaltatescuAnca Antonela NicolauDoina-Ecaterina TofoleanOana Cristina ArghirAriadna-Petronela FildanPublished in: Biomedicines (2023)
This review brings together the current knowledge regarding the risk factors and the clinical, radiologic, and histological features of both post-COVID-19 pulmonary fibrosis (PCPF) and idiopathic pulmonary fibrosis (IPF), describing the similarities and the disparities between these two diseases, using numerous databases to identify relevant articles published in English through October 2022. This review would help clinicians, pathologists, and researchers make an accurate diagnosis, which can help identify the group of patients selected for anti-fibrotic therapies and future therapeutic perspectives.
Keyphrases
- idiopathic pulmonary fibrosis
- pulmonary fibrosis
- coronavirus disease
- sars cov
- interstitial lung disease
- risk factors
- end stage renal disease
- newly diagnosed
- ejection fraction
- healthcare
- prognostic factors
- randomized controlled trial
- high resolution
- respiratory syndrome coronavirus
- machine learning
- mass spectrometry
- patient reported outcomes
- deep learning
- patient reported
- health insurance